A recent article on Kaiser Health News reported on a new drug for the treatment of hepatitis C for which the manufacturer charges $1,000 a pill, or $84,000 for a 12-week course of treatment.
Chronic hepatitis C is a leading cause of serious liver disease, including cancer.
It has been estimated that providing the drug to all patients known to have hepatitis C would substantially drive up budgets for public insurance programs and premiums for private insurance, though over the longer run there would be offsets to these upfront costs by obviating the need for alternative treatments, including liver transplants (see Pages 69-71 of the meeting summary from the California Technology Assessment Forum, linked to above).
The high price charged for the drug has led to street protests in San Francisco and calls for congressional hearings. It also provoked from The New York Times a stern editorial, “How Much Should Hepatitis C Treatment Cost?”
These reports brought to mind my post in November 2012. In that, I presented the above heuristic visual.
The horizontal line in this graph represents additional quality-adjusted life years (widely known in the research community as QALYs) wrestled from nature by a nation’s health system, arrayed in the increasing incremental costs per QALY gained. The vertical axis represents the incremental cost per additional QALY the health care system bestows on some patient.
I had called the solid line in the graph the QALY supply curve that the nation’s health system presents to society – the health system’s “offer curve,” in commercial parlance. A point on the line (e.g., Z) represents the most cost-effective (lowest cost) treatment capable of yielding the associated QALY. The treatment represented by point X would not be an efficient way to gain that QALY, because treatment Z is more cost-effective.
With this offer curve, a health system confronts the rest of the nation with two morally challenging questions:
1. Is there a maximum price above which society no longer wishes to purchase added QALYs from its health system, even with the most cost-effective treatments (e.g., Point C)?
2. Should that maximum price be the same for everyone, or could there be differentials – for example, a lower maximum price for patients covered by taxpayer-financed health programs (e.g., Medicaid, Tricare, the Veterans Administration health system and perhaps Medicare), a wide range of higher prices for premium-financed commercial insurance, depending on the generosity of the benefit package that the premium covers, and yet higher prices for wealthy people able to pay out of their own resources very high prices to purchases added QALYs for the family?
I tell my students that their parents and grandparents in the United States have always avoided confronting these morally taxing questions. They simply paid whatever was charged for whatever new medical technology came down the pike, letting per-capita health care spending grow annually at a long-term growth rate 2 to 2.5 percentage points above the growth in per-capita gross domestic product. The result has been spending far above the level of spending one observes in any other industrialized society (although we may implicitly have imposed a maximum price on QALYs for some Americans without health insurance).
But I also tell my students that they most likely will not be able to kick that particular can down the road much farther.
The Latest on: Quality-adjusted life years
via Google News
The Latest on: Quality-adjusted life years
- Marinomed announces trial of Carragelose in COVID-19 at Swansea University Medical Schoolon November 30, 2020 at 8:57 am
Marinomed Biotech AG announces clinical trial at Swansea University Medical School to investigate efficacy of Carragelose in preventing COVID-19 infections.
- Was lockdown worth the cost?on November 27, 2020 at 1:18 am
The standard way to compare the effectiveness of different types of healthcare spending is through assessing the number of additional “quality adjusted life years” – QALYs – achieved by ...
- Is the cure worse than the disease?on November 24, 2020 at 10:51 am
Dr Katie Musgrave shares why she feels that further lockdowns aren't a good idea ...
- Most Cost-effective to Use Immunotherapy First in Melanomaon November 24, 2020 at 5:06 am
The mean cost of up-front nivolumab monotherapy was $231,082 for 5.3 quality-adjusted life-years (QALYs); for pembrolizumab monotherapy, the mean cost was $236,111 for 7.4 QALYs; and for nivolumab ...
- Obamacare: 'What if they made you buy a product that ends your life?'on November 23, 2020 at 12:54 pm
Such deadly decisions are also made with a formula called QALY, quality-adjusted life years, which equals one year of life in perfect health. Here in the United States, QALY is championed by the ...
- A Covid Christmas and the price of lifeon November 23, 2020 at 10:14 am
Dr Hazel Chipchase on the care she received from stressed NHS staff, Dr Michael Peel on putting a price on lives. Plus John Yates and Ron Brewer on the coronavirus Christmas problem ...
- GUEST COMMENTARY: COVID's second wave underscores the threats facing disabled Americanson November 22, 2020 at 4:12 am
To conduct these cost-benefit analyses, ICER uses a controversial metric called a "quality-adjusted life year," or QALY. A treatment that adds a year of perfect health to a patient's life provides ...
- I will implement Free Primary Healthcare within a year – Mahamaon November 20, 2020 at 11:32 pm
Former President John Mahama says he will implement his promised Free Primary Healthcare within one year of being in office if he wins the December polls.
- Oaktree Specialty Lending Corporation (OCSL) CEO Armen Panossian on Q4 2020 Results - Earnings Call Transcripton November 19, 2020 at 4:56 pm
OCSL) Q4 2020 Earnings Conference Call November 19, 2020 11:00 AM ET Company Participants Michael Mosticchio - Investor Relations Armen Panossian - Chief Executive Officer and Chief Investment Officer ...
- Maintenance Olaparib May Be Cost-Effective for BRCA-Mutated Metastatic Pancreatic Canceron November 19, 2020 at 1:12 pm
Study results suggested that maintenance olaparib (Lynparza) is potentially cost-effective compared with placebo for patients with metastatic pancreatic cancer and a germline BRCA mutation.
via Bing News